Bayer announces positive topline results for NUBEQA (darolutamide) from Phase III trial in men with…
The Phase III ARANOTE trial, investigating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC),…
Read More...
Read More...